tiprankstipranks
Trending News
More News >
Atara Biotherapeutics Inc (ATRA)
:ATRA
Advertisement

Atara Biotherapeutics (ATRA) Stock Statistics & Valuation Metrics

Compare
1,156 Followers

Total Valuation

Atara Biotherapeutics has a market cap or net worth of $88.77M. The enterprise value is $131.17M.
Market Cap$88.77M
Enterprise Value$131.17M

Share Statistics

Atara Biotherapeutics has 7,023,032 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding7,023,032
Owned by Insiders42.07%
Owned by Institutions17.06%

Financial Efficiency

Atara Biotherapeutics’s return on equity (ROE) is 0.88 and return on invested capital (ROIC) is -3538.01%.
Return on Equity (ROE)0.88
Return on Assets (ROA)-0.78
Return on Invested Capital (ROIC)-3538.01%
Return on Capital Employed (ROCE)3.28
Revenue Per Employee842.75K
Profits Per Employee-558.19K
Employee Count153
Asset Turnover1.18
Inventory Turnover1.97

Valuation Ratios

The current PE Ratio of Atara Biotherapeutics is ―. Atara Biotherapeutics’s PEG ratio is ―.
PE Ratio
PS Ratio
PB Ratio
Price to Fair Value-1.02
Price to FCF
Price to Operating Cash Flow-2.28
PEG Ratio

Income Statement

In the last 12 months, Atara Biotherapeutics had revenue of 128.94M and earned -85.40M in profits. Earnings per share was -11.41.
Revenue128.94M
Gross Profit107.93M
Operating Income-83.44M
Pretax Income-85.42M
Net Income-85.40M
EBITDA-75.75M
Earnings Per Share (EPS)-11.41

Cash Flow

In the last 12 months, operating cash flow was -63.92M and capital expenditures -90.00K, giving a free cash flow of -64.01M billion.
Operating Cash Flow-63.92M
Free Cash Flow-64.01M
Free Cash Flow per Share-9.11

Dividends & Yields

Atara Biotherapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta0.95
52-Week Price Change74.93%
50-Day Moving Average10.36
200-Day Moving Average9.31
Relative Strength Index (RSI)58.88
Average Volume (3m)65.84K

Important Dates

Atara Biotherapeutics upcoming earnings date is Nov 18, 2025, TBA (Confirmed).
Last Earnings DateAug 11, 2025
Next Earnings DateNov 18, 2025
Ex-Dividend Date

Financial Position

Atara Biotherapeutics as a current ratio of 0.48, with Debt / Equity ratio of -44.02%
Current Ratio0.48
Quick Ratio0.40
Debt to Market Cap0.14
Net Debt to EBITDA-0.25
Interest Coverage Ratio-18.08

Taxes

In the past 12 months, Atara Biotherapeutics has paid -12.00K in taxes.
Income Tax-12.00K
Effective Tax Rate<0.01

Enterprise Valuation

Atara Biotherapeutics EV to EBITDA ratio is -1.56, with an EV/FCF ratio of -1.72.
EV to Sales0.92
EV to EBITDA-1.56
EV to Free Cash Flow-1.72
EV to Operating Cash Flow-1.72

Balance Sheet

Atara Biotherapeutics has $22.32M in cash and marketable securities with $15.43M in debt, giving a net cash position of -$6.90M billion.
Cash & Marketable Securities$22.32M
Total Debt$15.43M
Net Cash-$6.90M
Net Cash Per Share-$0.98
Tangible Book Value Per Share-$12.99

Margins

Gross margin is 79.32%, with operating margin of -64.71%, and net profit margin of -66.23%.
Gross Margin79.32%
Operating Margin-64.71%
Pretax Margin-66.24%
Net Profit Margin-66.23%
EBITDA Margin-58.75%
EBIT Margin-62.66%

Analyst Forecast

The average price target for Atara Biotherapeutics is $16.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$16.50
Price Target Upside33.60% Upside
Analyst ConsensusModerate Buy
Analyst Count3
Revenue Growth Forecast202.41%
EPS Growth Forecast98.99%

Scores

Smart Score8
AI Score53
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis